NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia · Delayed Price · Currency is AUD 0.0990
-0.0010 (-1.00%)
May 11, 2026, 9:59 AM AEST
NeuroScientific Biopharmaceuticals Company Description
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies.
Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve.
The company was incorporated in 2002 and is based in Cottesloe, Australia.
NeuroScientific Biopharmaceuticals Limited
| Country | Australia |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Nathan Smith |
Contact Details
Address: 216 St Georges Terrace Perth, Washington Washington Australia | |
| Phone | 61 8 6268 2641 |
Stock Details
| Ticker Symbol | NSB |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000012973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nathan Smith | Chief Executive Officer |
| Dr. Marian Sturm | Chief Scientific Officer |
| Dr. Catherine Cole | Chief Medical Officer |
| Christopher Bryan James Achurch B.Com., C.A. | Company Secretary |